日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism

骨髓基质细胞中 PYCR1 的抑制可通过改变其代谢来增强多发性骨髓瘤细胞对硼替佐米的敏感性。

Oudaert, Inge; van den Broecke, Lauren; Aksoy, Osman; Lind, Judith; Vallet, Sonia; Van der Vreken, Arne; Ates, Gamze; Massie, Ann; Maes, Ken; De Veirman, Kim; De Bruyne, Elke; Vanderkerken, Karin; Podar, Klaus; Menu, Eline

PARP7 as a new target for activating anti-tumor immunity in cancer

PARP7作为激活癌症抗肿瘤免疫的新靶点

Popova, Katerina; Benedum, Johannes; Engl, Magdalena; Lütgendorf-Caucig, Carola; Fossati, Piero; Widder, Joachim; Podar, Klaus; Slade, Dea

Dual therapeutic targeting of MYC and JUNB transcriptional programs for enhanced anti-myeloma activity.

双重治疗靶向 MYC 和 JUNB 转录程序以增强抗骨髓瘤活性

Lind Judith, Aksoy Osman, Prchal-Murphy Michaela, Fan Fengjuan, Fulciniti Mariateresa, Stoiber Dagmar, Bakiri Latifa, Wagner Erwin F, Zwickl-Traxler Elisabeth, Sattler Martin, Kollmann Karoline, Vallet Sonia, Podar Klaus

Correction: Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications

更正:Mcl-1赋予Her2阳性乳腺癌细胞对缺氧的保护作用:治疗意义

Bashari, Muhammad Hasan; Fan, Fengjuan; Vallet, Sonia; Sattler, Martin; Arn, Melissa; Luckner-Minden, Claudia; Schulze-Bergkamen, Henning; Zörnig, Inka; Marme, Frederik; Schneeweiss, Andreas; Cardone, Michael H; Opferman, Joseph T; Jäger, Dirk; Podar, Klaus

QoL during KTd or KRd induction followed by K maintenance or observation in transplant noneligible patients with newly diagnosed multiple myeloma: Longitudinal and cross-sectional analysis of the randomized AGMT 02 study

在不适合移植的新诊断多发性骨髓瘤患者中,接受KTd或KRd诱导治疗后,进行K维持治疗或观察期间的生活质量:AGMT 02随机研究的纵向和横断面分析

Ludwig, Heinz; Melchardt, Thomas; Schweitzer, Ilvy; Sormann, Siegfried; Schreder, Martin; Andel, Johannes; Hartmann, Bernd; Zojer, Niklas; Schöffmann, Laurenz; Gunsilius, Eberhard; Podar, Klaus; Egle, Alexander; Willenbacher, Wolfgang; Wöll, Ewald; Ruckser, Reinhard; Bozic, Boris; Krauth, Maria-Theresa; Petzer, Andreas; Schmitt, Clemens; Machherndl-Spandl, Sigrid; Agis, Hermine; Fillitz, Michael; Wang, Song-Yau; Knop, Stefan; Greil, Richard

Attrition Rates in Multiple Myeloma Treatment under Real World Conditions-An Analysis from the Austrian Myeloma Registry (AMR)

真实世界条件下多发性骨髓瘤治疗的脱落率——来自奥地利骨髓瘤登记处(AMR)的分析

Benda, Magdalena A; Ulmer, Hanno; Weger, Roman; Reimann, Patrick; Lang, Theresia; Pichler, Petra; Winder, Thomas; Hartmann, Bernd; Strassl, Irene; Krauth, Maria Theresa; Agis, Hermine; Sormann, Siegfried; Podar, Klaus; Willenbacher, Wolfgang; Willenbacher, Ella

Evaluation of Antibody Responses in Patients with B-Cell Malignancies after Two and Three Doses of Anti-SARS-CoV-2 S Vaccination-A Retrospective Cohort Study

评估B细胞恶性肿瘤患者接种两剂和三剂抗SARS-CoV-2 S疫苗后的抗体反应——一项回顾性队列研究

Wirth, Stella Rosa Maria; Podar, Klaus; Pecherstorfer, Martin; Wohlfarth, Philipp; Jaeger, Ulrich; Singer, Josef

Publisher Correction: JunB is a key regulator of multiple myeloma bone marrow angiogenesis

出版商更正:JunB是多发性骨髓瘤骨髓血管生成的关键调控因子

Fan, Fengjuan; Malvestiti, Stefano; Vallet, Sonia; Lind, Judith; Garcia-Manteiga, Jose Manuel; Morelli, Eugenio; Jiang, Qinyue; Seckinger, Anja; Hose, Dirk; Goldschmidt, Hartmut; Stadlbauer, Andreas; Sun, Chunyan; Mei, Heng; Pecherstorfer, Martin; Bakiri, Latifa; Wagner, Erwin F; Tonon, Giovanni; Sattler, Martin; Hu, Yu; Tassone, Pierfrancesco; Jaeger, Dirk; Podar, Klaus

Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond

2020/2021 年及以后的复发/难治性多发性骨髓瘤

Podar, Klaus; Leleu, Xavier

Evaluation of Antibody Responses to COVID-19 Vaccines among Solid Tumor and Hematologic Patients

评估实体瘤和血液病患者对新冠疫苗的抗体反应

Singer, Josef; Le, Nguyen-Son; Mattes, Daniel; Klamminger, Valerie; Hackner, Klaus; Kolinsky, Nicole; Scherb, Michaela; Errhalt, Peter; Kreye, Gudrun; Pecherstorfer, Martin; Vallet, Sonia; Podar, Klaus